Phio Pharmaceuticals Stock to Reverse Split on Friday, July 5th (NASDAQ:PHIO)

Phio Pharmaceuticals Corp. (NASDAQ:PHIO)’s stock is set to reverse split before the market opens on Friday, July 5th. The 1-9 reverse split was announced on Friday, July 5th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, July 5th.

Phio Pharmaceuticals Stock Down 4.8 %

PHIO stock traded down $0.03 during trading on Wednesday, hitting $0.58. The company had a trading volume of 133,033 shares, compared to its average volume of 264,498. The firm has a 50-day moving average price of $0.74 and a 200-day moving average price of $0.74. The stock has a market cap of $2.67 million, a price-to-earnings ratio of -0.19 and a beta of 1.45. Phio Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.23.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its earnings results on Thursday, May 9th. The company reported ($0.47) EPS for the quarter. Equities analysts expect that Phio Pharmaceuticals will post -1.82 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Phio Pharmaceuticals in a research report on Tuesday, May 14th.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.